Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,750 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketamine for Depression: An MRI Study

NCT02544607
Conditions
Depression, Anxious Depression, Major Depressive Disorder
Interventions
Ketamine, Magnetic Resonance Imaging (MRI)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Major Depressive Disorder, Depression, Bipolar Disorder, Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions
emotional memory training exercise, memory training exercise
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
NMRA-335140, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Cerritos, California • Irvine, California • Long Beach, California + 27 more
Conditions
Depression - Major Depressive Disorder
Interventions
transcutaneous spinal direct current stimulation
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mason, Ohio
Conditions
Major Depressive Disorder
Interventions
Dose-matched placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
Conditions
Major Depressive Disorder
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more
Conditions
Major Depressive Disorder
Interventions
Approach-positive AAT, Control AAT
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Completed Not applicable Interventional Results available

Mechanisms of Antidepressant Non-Response in Late-Life Depression

NCT01931202
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo oral tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Terminated Not applicable Interventional Results available

rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2

NCT01804296
Conditions
Major Depressive Disorder
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Paul E. Croarkin
Other
Eligibility
12 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Charleston, South Carolina
Conditions
Major Depressive Disorder
Interventions
repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Neuronetics
Other
Eligibility
22 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Treatment Resistant Depression
Interventions
Direct Neural Electrical Stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Months to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Depression, Depressive Disorder, Major
Interventions
CAD-MDD/CAT-DI screening via MyChart, CAD-MDD/CAT-DI screening during clinic visit, CAT-DI monitoring via MyChart, PHQ-9 monitoring during clinic visits
Diagnostic Test · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Correlates of Stress and Perceived Control in Adolescent Depression

NCT04788524
Conditions
Major Depressive Disorder
Interventions
Computer Task Manipulation
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Depression
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Major Depressive Disorder
Interventions
Behavioral Activation, Fluoxetine
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 4 Interventional Results available

Memantine Augmentation of Antidepressants

NCT00344682
Conditions
Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
HOPES-I
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Concord, New Hampshire • Nashua, New Hampshire
Conditions
Major Depressive Disorder
Interventions
NG-nitro-L-arginine methyl ester (L-NAME)
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Newark, Delaware
Completed Not applicable Interventional Accepts healthy volunteers Results available

fMRI Study of Treatment Changes in Major Depression

NCT01027559
Conditions
Major Depression, Treatment
Interventions
Sertraline, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more